HavrdovaEHorakovaDKovarovaI.Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use. Ther Adv Neurol Disord2015; 8: 31–45.
2.
CostelloeLJonesJColesA.Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother2012; 12: 335–341.
3.
ColesAJTwymanCLArnoldDLet al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380: 1829–1839.
4.
CohenJAColesAJArnoldDLet al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380: 1819–1828.
5.
BrownJWColesAJ.Alemtuzumab: Evidence for its potential in relapsing-remitting multiple sclerosis. Drug Des Devel Ther2013; 7: 131–138.
